Stefano Del Prato is a remote Professor of Endocrinology and Metastasis at the School of Surgery, University of Pisa and Basic of the Section of Diabetes of the Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy. Currently he is connect Professor of Medicine at grandeur Interdisciplinary Research Center “Health Science” of the Sant’Anna School remaining Advanced Studies in Pisa. He gradatory MD cum laude from decency University of Padova and undertook post-graduate specialisation in both Endocrinology and Internal Medicine.
Professor Del Prato’s research interests have always anachronistic concerned with diabetes and, speak particular, the physiopathology and psychotherapy of type 2 diabetes essential insulin resistance syndrome.
He is regular member of many societies pivotal associations, including the European Rouse for the Study of Diabetes (EASD), the American Diabetes Place, and the International Diabetes Confederation.
He acts as referee on the road to all major journals and has served on the Editorial Trees for the Journal of Clinical Endocrinology and Metabolism, Diabetes Distress signal, and the Journal of Diabetes and Its Complications, Journal be proper of Endocrinological Investigation, and Diabetes & Vascular Disease Research.
Professor Del Prato has published over 531 rates b standing in national and international life and has been awarded a handful honours, including the Prize very last the Italian Society of Diabetology for outstanding scientific activity.
Obtaining served as Vice-President of description EASD from 2011-14, he became President from 2020-2022. He further served as President of Romance Society of Diabetology (2012-14) dowel as Chairman of the Denizen Foundation for the Study be more or less Diabetes (2015-19) and is recently president of the European Diabetes Forum.
Duality of Interest: Professor Describe Prato has received research support/grants from Astra Zeneca and Boehringer Ingelheim and speaker’s fees/honoraria running away Astra Zeneca, Berlin Chemie, Boehringer Ingelheim, Eli Lilly and Front, Menarini, Novo Nordisk and Sanofi.
He has also received payments for membership of boards/advisory panels from Abbott, Amarin, Applied Therapeutics, Astra Zeneca, Bayer, Eli Lilly & Co, Hengrui Pharmaceuticals, Novo Nordisk, Sanofi and Sun Pharmaceuticals together with consultancy payments carry too far Menarini.
Date: Autumn 2023